{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T19:49:26Z","timestamp":1794772166687,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA287782"],"award-info":[{"award-number":["R01 CA287782"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA266613"],"award-info":[{"award-number":["R01 CA266613"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA257906"],"award-info":[{"award-number":["P01 CA257906"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA138292"],"award-info":[{"award-number":["P50 CA138292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chemotherapy is often a primary treatment for cancer. However, resistance leads to therapeutic failure. Acetylation dynamics play important regulatory roles in cancer cells, but the mechanisms by which acetylation mediates therapy resistance remain poorly understood. Here, using acetylome-focused RNA interference (RNAi) screening, we find that acetylation induced by mitochondrial dihydrolipoyl transacetylase (DLAT), independent of the pyruvate dehydrogenase complex, is pivotal in promoting resistance to chemotherapeutics, such as cisplatin. Mechanistically, DLAT acetylates methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) at lysine 44 and promotes 10-formyl-tetrahydrofolate (10-formyl-THF) and consequent mitochondrially encoded cytochrome c oxidase II (MT-CO2) induction. DLAT signaling is elevated in cancer patients refractory to chemotherapy or chemoimmunotherapy. A decoy peptide DMp39, designed to target DLAT signaling, effectively sensitizes cancer cells to cisplatin in patient-derived xenograft models. Collectively, our study reveals the crucial role of DLAT in shaping chemotherapy resistance, which involves an interplay between acetylation signaling and metabolic reprogramming, and offers a unique decoy peptide technology to overcome chemotherapy resistance.<\/jats:p>","DOI":"10.1038\/s41467-025-63892-3","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:20:49Z","timestamp":1759915249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Non-canonical dihydrolipoyl transacetylase promotes chemotherapy resistance via mitochondrial tetrahydrofolate signaling"],"prefix":"10.1038","volume":"16","author":[{"given":"Jung Seok","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiHoon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoung","family":"Eun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Bacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Avalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Shuff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong M.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4972-1477","authenticated-orcid":false,"given":"Nabil F.","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly R.","family":"Magliocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4256-8652","authenticated-orcid":false,"given":"Cheng-Kui","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2362-7979","authenticated-orcid":false,"given":"Haian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-3106","authenticated-orcid":false,"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7476-1329","authenticated-orcid":false,"given":"Andrey A.","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2898-6831","authenticated-orcid":false,"given":"Taro","family":"Hitosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5111-0232","authenticated-orcid":false,"given":"Sumin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"63892_CR1","unstructured":"Brown, A., Kumar, S. & Tchounwou, P. B. Cisplatin-Based Chemotherapy of Human Cancers. J. Cancer Sci. Ther. 11, 97 (2019)."},{"key":"63892_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102360","volume":"104","author":"A Martini","year":"2022","unstructured":"Martini, A. et al. Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis. Cancer Treat. Rev. 104, 102360 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"63892_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2478\/raon-2019-0018","volume":"53","author":"T Makovec","year":"2019","unstructured":"Makovec, T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radio. Oncol. 53, 148\u2013158 (2019).","journal-title":"Radio. Oncol."},{"key":"63892_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/157489206777442287","volume":"1","author":"MS Galanski","year":"2006","unstructured":"Galanski, M. S. Recent Developments in the Field of Anticancer Platinum Complexes. Recent Pat. Anticancer Drug Discov. 1, 285\u2013295 (2006).","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"63892_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/JEP.S267383","volume":"13","author":"PB Tchounwou","year":"2021","unstructured":"Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P. & Kumar, S. Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy. J. Exp. Pharm. 13, 303\u2013328 (2021).","journal-title":"J. Exp. Pharm."},{"key":"63892_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4046\/trd.2018.0068","volume":"82","author":"SH Lee","year":"2019","unstructured":"Lee, S. H. Chemotherapy for Lung Cancer in the Era of Personalized Medicine. Tuberc. Respir. Dis. (Seoul.) 82, 179\u2013189 (2019).","journal-title":"Tuberc. Respir. Dis. (Seoul.)"},{"key":"63892_CR7","doi-asserted-by":"publisher","first-page":"e0200509","DOI":"10.1371\/journal.pone.0200509","volume":"13","author":"YR Kim","year":"2018","unstructured":"Kim, Y. R., Lee, B., Byun, M. R., Lee, J. K. & Choi, J. W. Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer. PloS one 13, e0200509 (2018).","journal-title":"PloS one"},{"key":"63892_CR8","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.annonc.2021.02.015","volume":"32","author":"T Baert","year":"2021","unstructured":"Baert, T. et al. The systemic treatment of recurrent ovarian cancer revisited. Ann. Oncol. 32, 710\u2013725 (2021).","journal-title":"Ann. Oncol."},{"key":"63892_CR9","doi-asserted-by":"crossref","unstructured":"Sordo-Bahamonde, C. et al. Chemo-Immunotherapy: A New Trend in Cancer Treatment. Cancers (Basel) 15, 2912 (2023).","DOI":"10.3390\/cancers15112912"},{"key":"63892_CR10","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869\u20131883 (2012).","journal-title":"Oncogene"},{"key":"63892_CR11","first-page":"304","volume":"5","author":"M Ortiz","year":"2022","unstructured":"Ortiz, M., Wabel, E., Mitchell, K. & Horibata, S. Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist 5, 304\u2013316 (2022).","journal-title":"Cancer Drug Resist"},{"key":"63892_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.265","volume":"4","author":"ZN Lei","year":"2023","unstructured":"Lei, Z. N. et al. Understanding and targeting resistance mechanisms in cancer. MedComm (2020) 4, e265 (2023).","journal-title":"MedComm (2020)"},{"key":"63892_CR13","doi-asserted-by":"crossref","unstructured":"Lugones, Y., Loren, P. & Salazar, L. A. Cisplatin Resistance: Genetic and Epigenetic Factors Involved. Biomolecules 12, 1365 (2022).","DOI":"10.3390\/biom12101365"},{"key":"63892_CR14","doi-asserted-by":"crossref","unstructured":"Chen, S. H. & Chang, J. Y. New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment. Int. J. Mol. Sci. 20, 4136 (2019).","DOI":"10.3390\/ijms20174136"},{"key":"63892_CR15","doi-asserted-by":"publisher","first-page":"691795","DOI":"10.3389\/fmolb.2021.691795","volume":"8","author":"L Wang","year":"2021","unstructured":"Wang, L., Zhao, X., Fu, J., Xu, W. & Yuan, J. The Role of Tumour Metabolism in Cisplatin Resistance. Front Mol. Biosci. 8, 691795 (2021).","journal-title":"Front Mol. Biosci."},{"key":"63892_CR16","doi-asserted-by":"crossref","unstructured":"Wangpaichitr, M. et al. Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration. Int. J. Mol. Sci. 22, 7379 (2021).","DOI":"10.3390\/ijms22147379"},{"key":"63892_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.972312","volume":"13","author":"J Yang","year":"2022","unstructured":"Yang, J., Song, C. & Zhan, X. The role of protein acetylation in carcinogenesis and targeted drug discovery. Front Endocrinol. (Lausanne) 13, 972312 (2022).","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"63892_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01615-5","volume":"16","author":"A Natu","year":"2024","unstructured":"Natu, A. et al. Histone acetylation: a key determinant of acquired cisplatin resistance in cancer. Clin. Epigenetics 16, 8 (2024).","journal-title":"Clin. Epigenetics"},{"key":"63892_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13046-020-1536-x","volume":"39","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1\/c-Jun\/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. J. Exp. Clin. Cancer Res 39, 29 (2020).","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"63892_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188568","volume":"1876","author":"S Anwar","year":"2021","unstructured":"Anwar, S., Shamsi, A., Mohammad, T., Islam, A. & Hassan, M. I. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy. Biochim Biophys. Acta Rev. Cancer 1876, 188568 (2021).","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"63892_CR21","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/ijc.29564","volume":"138","author":"E Saunier","year":"2016","unstructured":"Saunier, E., Benelli, C. & Bortoli, S. The pyruvate dehydrogenase complex in cancer: An old metabolic gatekeeper regulated by new pathways and pharmacological agents. Int J. Cancer 138, 809\u2013817 (2016).","journal-title":"Int J. Cancer"},{"key":"63892_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cell.2014.04.046","volume":"158","author":"G Sutendra","year":"2014","unstructured":"Sutendra, G. et al. A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell 158, 84\u201397 (2014).","journal-title":"Cell"},{"key":"63892_CR23","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1096\/fasebj.4.14.2227213","volume":"4","author":"MS Patel","year":"1990","unstructured":"Patel, M. S. & Roche, T. E. Molecular biology and biochemistry of pyruvate dehydrogenase complexes. FASEB J. 4, 3224\u20133233 (1990).","journal-title":"FASEB J."},{"key":"63892_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0079-6603(01)70013-X","volume":"70","author":"TE Roche","year":"2001","unstructured":"Roche, T. E. et al. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog. Nucleic Acid Res Mol. Biol. 70, 33\u201375 (2001).","journal-title":"Prog. Nucleic Acid Res Mol. Biol."},{"key":"63892_CR25","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.1074\/jbc.M308172200","volume":"279","author":"Y Hiromasa","year":"2004","unstructured":"Hiromasa, Y., Fujisawa, T., Aso, Y. & Roche, T. E. Organization of the cores of the mammalian pyruvate dehydrogenase complex formed by E2 and E2 plus the E3-binding protein and their capacities to bind the E1 and E3 components. J. Biol. Chem. 279, 6921\u20136933 (2004).","journal-title":"J. Biol. Chem."},{"key":"63892_CR26","doi-asserted-by":"publisher","first-page":"16615","DOI":"10.1074\/jbc.R114.563148","volume":"289","author":"MS Patel","year":"2014","unstructured":"Patel, M. S., Nemeria, N. S., Furey, W. & Jordan, F. The pyruvate dehydrogenase complexes: structure-based function and regulation. J. Biol. Chem. 289, 16615\u201316623 (2014).","journal-title":"J. Biol. Chem."},{"key":"63892_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0065-2571(01)00061-9","volume":"42","author":"RA Harris","year":"2002","unstructured":"Harris, R. A., Bowker-Kinley, M. M., Huang, B. & Wu, P. Regulation of the activity of the pyruvate dehydrogenase complex. Adv. Enzym. Regul. 42, 249\u2013259 (2002).","journal-title":"Adv. Enzym. Regul."},{"key":"63892_CR28","first-page":"1140","volume":"7","author":"WQ Goh","year":"2015","unstructured":"Goh, W. Q., Ow, G. S., Kuznetsov, V. A., Chong, S. & Lim, Y. P. DLAT subunit of the pyruvate dehydrogenase complex is upregulated in gastric cancer-implications in cancer therapy. Am. J. Transl. Res 7, 1140\u20131151 (2015).","journal-title":"Am. J. Transl. Res"},{"key":"63892_CR29","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.3390\/curroncol30030228","volume":"30","author":"Z Fang","year":"2023","unstructured":"Fang, Z. et al. Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Preliminary Study Based on Bioinformatics Analysis. Curr. Oncol. 30, 2997\u20133019 (2023).","journal-title":"Curr. Oncol."},{"key":"63892_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43835-y","volume":"13","author":"P Zhang","year":"2023","unstructured":"Zhang, P. et al. DLAT is a promising prognostic marker and therapeutic target for hepatocellular carcinoma: a comprehensive study based on public databases. Sci. Rep. 13, 17295 (2023).","journal-title":"Sci. Rep."},{"key":"63892_CR31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0167-4781(93)90066-M","volume":"1171","author":"KG Peri","year":"1993","unstructured":"Peri, K. G. & MacKenzie, R. E. NAD(+)-dependent methylenetetrahydrofolate dehydrogenase-cyclohydrolase: detection of the mRNA in normal murine tissues and transcriptional regulation of the gene in cell lines. Biochim Biophys. Acta 1171, 281\u2013287 (1993).","journal-title":"Biochim Biophys. Acta"},{"key":"63892_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4128","volume":"5","author":"R Nilsson","year":"2014","unstructured":"Nilsson, R. et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat. Commun. 5, 3128 (2014).","journal-title":"Nat. Commun."},{"key":"63892_CR33","doi-asserted-by":"publisher","first-page":"8685","DOI":"10.1007\/s13277-014-2111-x","volume":"35","author":"F Liu","year":"2014","unstructured":"Liu, F. et al. Increased MTHFD2 expression is associated with poor prognosis in breast cancer. Tumour Biol. 35, 8685\u20138690 (2014).","journal-title":"Tumour Biol."},{"key":"63892_CR34","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.dld.2016.04.015","volume":"48","author":"X Liu","year":"2016","unstructured":"Liu, X. et al. Methylenetetrahydrofolate dehydrogenase 2 overexpression is associated with tumor aggressiveness and poor prognosis in hepatocellular carcinoma. Dig. Liver Dis. 48, 953\u2013960 (2016).","journal-title":"Dig. Liver Dis."},{"key":"63892_CR35","first-page":"1827","volume":"16","author":"K Noguchi","year":"2018","unstructured":"Noguchi, K. et al. The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer. Oncol. Lett. 16, 1827\u20131834 (2018).","journal-title":"Oncol. Lett."},{"key":"63892_CR36","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41419-020-02825-y","volume":"11","author":"X Wan","year":"2020","unstructured":"Wan, X. et al. Cisplatin inhibits SIRT3-deacetylation MTHFD2 to disturb cellular redox balance in colorectal cancer cell. Cell death Dis. 11, 649 (2020).","journal-title":"Cell death Dis."},{"key":"63892_CR37","doi-asserted-by":"crossref","unstructured":"Zhang, F. et al. Deacetylation of MTHFD2 by SIRT4 senses stress signal to inhibit cancer cell growth by remodeling folate metabolism. J. Mol. Cell Biol. 14, mjac020 (2022).","DOI":"10.1093\/jmcb\/mjac020"},{"key":"63892_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22173-5","volume":"12","author":"M Shang","year":"2021","unstructured":"Shang, M. et al. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation. Nat. Commun. 12, 1940 (2021).","journal-title":"Nat. Commun."},{"key":"63892_CR39","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1056\/NEJM198308183090702","volume":"309","author":"PW Stacpoole","year":"1983","unstructured":"Stacpoole, P. W., Harman, E. M., Curry, S. H., Baumgartner, T. G. & Misbin, R. I. Treatment of lactic acidosis with dichloroacetate. N. Engl. J. Med. 309, 390\u2013396 (1983).","journal-title":"N. Engl. J. Med."},{"key":"63892_CR40","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1158\/0008-5472.CAN-16-1476","volume":"77","author":"R Gustafsson","year":"2017","unstructured":"Gustafsson, R. et al. Crystal Structure of the Emerging Cancer Target MTHFD2 in Complex with a Substrate-Based Inhibitor. Cancer Res. 77, 937\u2013948 (2017).","journal-title":"Cancer Res."},{"key":"63892_CR41","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1021\/acsmedchemlett.9b00069","volume":"10","author":"J Kawai","year":"2019","unstructured":"Kawai, J. et al. Structure-Based Design and Synthesis of an Isozyme-Selective MTHFD2 Inhibitor with a Tricyclic Coumarin Scaffold. ACS Med Chem. Lett. 10, 893\u2013898 (2019).","journal-title":"ACS Med Chem. Lett."},{"key":"63892_CR42","doi-asserted-by":"publisher","first-page":"10204","DOI":"10.1021\/acs.jmedchem.9b01113","volume":"62","author":"J Kawai","year":"2019","unstructured":"Kawai, J. et al. Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity. J. Med. Chem. 62, 10204\u201310220 (2019).","journal-title":"J. Med. Chem."},{"key":"63892_CR43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s43018-022-00331-y","volume":"3","author":"N Bonagas","year":"2022","unstructured":"Bonagas, N. et al. Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress. Nat. Cancer 3, 156\u2013172 (2022).","journal-title":"Nat. Cancer"},{"key":"63892_CR44","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1038\/s41388-021-01695-8","volume":"40","author":"LN Zhao","year":"2021","unstructured":"Zhao, L. N., Bjorklund, M., Caldez, M. J., Zheng, J. & Kaldis, P. Therapeutic targeting of the mitochondrial one-carbon pathway: perspectives, pitfalls, and potential. Oncogene 40, 2339\u20132354 (2021).","journal-title":"Oncogene"},{"key":"63892_CR45","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ccell.2018.06.012","volume":"34","author":"L Jin","year":"2018","unstructured":"Jin, L. et al. MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer cell 34, 315\u2013330.e7 (2018).","journal-title":"Cancer cell"},{"key":"63892_CR46","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202300980R","volume":"37","author":"H Wen","year":"2023","unstructured":"Wen, H. et al. Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT\/mTOR pathway in prostate cancer. FASEB J. 37, e23145 (2023).","journal-title":"FASEB J."},{"key":"63892_CR47","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41420-022-01130-1","volume":"8","author":"C Wang","year":"2022","unstructured":"Wang, C. et al. Novel role of COX6c in the regulation of oxidative phosphorylation and diseases. Cell Death Discov. 8, 336 (2022).","journal-title":"Cell Death Discov."},{"key":"63892_CR48","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.18632\/oncotarget.3015","volume":"6","author":"CR Oliva","year":"2015","unstructured":"Oliva, C. R., Markert, T., Gillespie, G. Y. & Griguer, C. E. Nuclear-encoded cytochrome c oxidase subunit 4 regulates BMI1 expression and determines proliferative capacity of high-grade gliomas. Oncotarget 6, 4330\u20134344 (2015).","journal-title":"Oncotarget"},{"key":"63892_CR49","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.molcel.2018.01.024","volume":"69","author":"DR Minton","year":"2018","unstructured":"Minton, D. R. et al. Serine Catabolism by SHMT2 Is Required for Proper Mitochondrial Translation Initiation and Maintenance of Formylmethionyl-tRNAs. Mol. cell 69, 610\u2013621.e615 (2018).","journal-title":"Mol. cell"},{"key":"63892_CR50","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1158\/1535-7163.MCT-14-0420","volume":"14","author":"HQ Ju","year":"2015","unstructured":"Ju, H. Q. et al. Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation. Mol. cancer therapeutics 14, 788\u2013798 (2015).","journal-title":"Mol. cancer therapeutics"},{"key":"63892_CR51","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1111\/jcmm.17799","volume":"27","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC. J. Cell Mol. Med 27, 2032\u20132044 (2023).","journal-title":"J. Cell Mol. Med"},{"key":"63892_CR52","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/1534735404270335","volume":"3","author":"KA Conklin","year":"2004","unstructured":"Conklin, K. A. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr. Cancer Ther. 3, 294\u2013300 (2004).","journal-title":"Integr. Cancer Ther."},{"key":"63892_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1257107","volume":"14","author":"H Tang","year":"2023","unstructured":"Tang, H. & Hou, N. Whether MTHFD2 plays a new role: from anticancer targets to anti-inflammatory disease. Front Pharm. 14, 1257107 (2023).","journal-title":"Front Pharm."},{"key":"63892_CR54","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.drudis.2020.01.010","volume":"25","author":"M Mahjoubin-Tehran","year":"2020","unstructured":"Mahjoubin-Tehran, M. et al. Peptide decoys: a new technology offering therapeutic opportunities for breast cancer. Drug Discov. Today 25, 593\u2013598 (2020).","journal-title":"Drug Discov. Today"},{"key":"63892_CR55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","volume":"7","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Therapeutic peptides: current applications and future directions. Signal Transduct. Target Ther. 7, 48 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"63892_CR56","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","volume":"10","author":"FM Veronese","year":"2005","unstructured":"Veronese, F. M. & Pasut, G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451\u20131458 (2005).","journal-title":"Drug Discov. Today"},{"key":"63892_CR57","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","volume":"17","author":"L Di","year":"2015","unstructured":"Di, L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 17, 134\u2013143 (2015).","journal-title":"AAPS J."},{"key":"63892_CR58","doi-asserted-by":"publisher","first-page":"7248","DOI":"10.1158\/1078-0432.CCR-11-0690","volume":"17","author":"M Zhao","year":"2011","unstructured":"Zhao, M. et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 17, 7248\u20137264 (2011).","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"63892_CR59","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1172\/JCI40582","volume":"120","author":"S Kang","year":"2010","unstructured":"Kang, S. et al. p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J. Clin. Investig. 120, 1165\u20131177 (2010).","journal-title":"J. Clin. Investig."},{"key":"63892_CR60","doi-asserted-by":"publisher","first-page":"32528","DOI":"10.1074\/jbc.M113.500561","volume":"288","author":"D Li","year":"2013","unstructured":"Li, D. et al. The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis. J. Biol. Chem. 288, 32528\u201332538 (2013).","journal-title":"J. Biol. Chem."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63892-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63892-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63892-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:03:26Z","timestamp":1759917806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63892-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63892"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63892-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8932"}}